Jorge Mestre-Ferrandiz

Office of Health Economics

12 Whitehall

London, SW1A 2DY

United Kingdom

  • Office of Health Economics

SCHOLARLY PAPERS

9

DOWNLOADS

936

TOTAL CITATIONS

5

Scholarly Papers (9)

Actions:
Email selected abstracts
1.

Access Mechanisms for Orphan Drugs: A Comparative Study of Selected European Countries

OHE Briefing, No. 52, October 2009
Number of pages: 32 Posted: 27 Aug 2015
Martina Garau and Jorge Mestre-Ferrandiz
Office of Health Economics and Office of Health Economics
Downloads 225 (283,619)

Abstract:

Loading...

2.

Business Model Options for Antibiotics: Learning from Other Industries

Chatham House, The Royal Institute of International Affairs (London) and the Big Innovation Centre (London), 2015, Boston Univ. School of Law, Public Law Research Paper No. 15-05
Number of pages: 43 Posted: 25 Feb 2015
Ella Jaczynska, Kevin Outterson and Jorge Mestre-Ferrandiz
GlaxoSmithKline, Boston University School of Law and Office of Health Economics
Downloads 156 (395,177)

Abstract:

Loading...

antibiotics, innovation, new drugs, resistance

3.

What is the Role of HTA for Biosimilars?

Number of pages: 48 Posted: 25 Aug 2015
Jorge Mestre-Ferrandiz and Adrian Towse
Office of Health Economics and Office of Health Economics
Downloads 154 (399,477)
Citation 3

Abstract:

Loading...

4.

The Market for Biosimilars: Evolution and Policy Options

OHE Briefing, No. 45, October 2008
Number of pages: 24 Posted: 27 Aug 2015
Deven Chauhan, Adrian Towse and Jorge Mestre-Ferrandiz
Merck & Co., Inc. - Merck Serono Company, Office of Health Economics and Office of Health Economics
Downloads 96 (571,816)

Abstract:

Loading...

5.

Value-Based Differential Pricing: Efficient Prices for Drugs in a Global Context

NBER Working Paper No. w18593
Number of pages: 23 Posted: 07 Dec 2012 Last Revised: 22 Apr 2023
Patricia M. Danzon, Patricia M. Danzon, Adrian Towse and Jorge Mestre-Ferrandiz
University of Pennsylvania - The Wharton SchoolThe Wharton School, Univ. of Pennsylvania, Office of Health Economics and Office of Health Economics
Downloads 87 (607,768)

Abstract:

Loading...

6.

The Current Drug Development Paradigm: Responding to US and European Demands for Evidence of Comparative Effectiveness and Relative Effectiveness

Number of pages: 57 Posted: 23 Aug 2015
Jorge Mestre-Ferrandiz, Patricia Deverka, Michele Pistallato and Emily Rosenberg
Office of Health Economics, Center for Medical Technology Policy (CMTP), Office of Health Economics and Center for Medical Technology Policy (CMTP)
Downloads 68 (697,166)
Citation 1

Abstract:

Loading...

7.

Projecting Expenditure on Medicines in the NHS (Second Edition)

Office of Health Economics Research Paper 14/01
Number of pages: 47 Posted: 15 Aug 2015
Phill Peter O'Neill, Jorge Mestre-Ferrandiz, Ruth Puig-Peiro and Jon Sussex
Office of Health Economics, Office of Health Economics, Office of Health Economics and RAND Europe
Downloads 62 (730,757)
Citation 1

Abstract:

Loading...

8.

The Faces of Regulation Profit and Price Regulation of the UK Pharmaceutical Industry after the 1998 Competition Act

OHE Briefing, No. 41, May 2006
Number of pages: 24 Posted: 27 Aug 2015
Jorge Mestre-Ferrandiz
Office of Health Economics
Downloads 57 (761,182)

Abstract:

Loading...

9.

Projecting Expenditure on Medicines in the NHS

Number of pages: 35 Posted: 16 Aug 2015
Phill Peter O'Neill, Jorge Mestre-Ferrandiz, Ruth Puig-Peiro and Jon Sussex
Office of Health Economics, Office of Health Economics, Office of Health Economics and RAND Europe
Downloads 31 (974,380)

Abstract:

Loading...